Next Article in Journal
Efficacy of Lesion Specific Portals in Endoscopic Treatment of Calcaneal Bone Cyst: A Case Report and Literature Review
Next Article in Special Issue
Pulmonary Hypertension in Pregnancy: A Review
Previous Article in Journal
The Role of New Technologies to Prevent Suicide in Adolescence: A Systematic Review of the Literature
Previous Article in Special Issue
Revisiting One of the Dreaded Outcomes of the Current Pandemic: Pulmonary Embolism in COVID-19
Review

Review of Medical Therapies for the Management of Pulmonary Embolism

Department of Pharmacy Practice, Texas A&M Rangel College of Pharmacy, 1010 W Ave B, Kingsville, TX 78363, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Pierpaolo Di Micco
Received: 1 December 2020 / Revised: 11 January 2021 / Accepted: 13 January 2021 / Published: 26 January 2021
(This article belongs to the Special Issue Pulmonary Embolism Research)
Traditionally, the management of patients with pulmonary embolism has been accomplished with anticoagulant treatment with parenteral heparins and oral vitamin K antagonists. Although the administration of heparins and oral vitamin K antagonists still plays a role in pulmonary embolism management, the use of these therapies are limited due to other options now available. This is due to their toxicity profile, clearance limitations, and many interactions with other medications and nutrients. The emergence of direct oral anticoagulation therapies has led to more options now being available to manage pulmonary embolism in inpatient and outpatient settings conveniently. These oral therapeutic options have opened up opportunities for safe and effective pulmonary embolism management, as more evidence and research is now available about reversal agents and monitoring parameters. The evolution of the pharmacological management of pulmonary embolism has provided us with better understanding regarding the selection of anticoagulants. There is also a better understanding and employment of anticoagulants in pulmonary embolism in special populations, such as patients with liver failure, renal failure, malignancy, and COVID-19. View Full-Text
Keywords: pulmonary embolism (PE); venous thromboembolism (VTE); anticoagulants; direct oral anticoagulants (DOAC) pulmonary embolism (PE); venous thromboembolism (VTE); anticoagulants; direct oral anticoagulants (DOAC)
MDPI and ACS Style

Panahi, L.; Udeani, G.; Horseman, M.; Weston, J.; Samuel, N.; Joseph, M.; Mora, A.; Bazan, D. Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina 2021, 57, 110. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57020110

AMA Style

Panahi L, Udeani G, Horseman M, Weston J, Samuel N, Joseph M, Mora A, Bazan D. Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina. 2021; 57(2):110. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57020110

Chicago/Turabian Style

Panahi, Ladan, George Udeani, Michael Horseman, Jaye Weston, Nephy Samuel, Merlyn Joseph, Andrea Mora, and Daniela Bazan. 2021. "Review of Medical Therapies for the Management of Pulmonary Embolism" Medicina 57, no. 2: 110. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57020110

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop